These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19455057)

  • 1. TNFalpha inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma.
    Stoll ML; Solomon DH; Batra KL; Simard JF; Karlson EW; Dellaripa PF; Weinblatt ME; Glass R; Shadick NA
    J Clin Rheumatol; 2009 Jun; 15(4):198-200. PubMed ID: 19455057
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 3. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-TNF agents for rheumatoid arthritis.
    Seymour HE; Worsley A; Smith JM; Thomas SH
    Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 6. [Inhibitors of TNFalpha].
    Brousse C
    Rev Med Interne; 2003 Feb; 24(2):123-6. PubMed ID: 12650894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF therapy in rheumatoid arthritis].
    Yakeuchi T; Amano K
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):7-15. PubMed ID: 15045810
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Sidiropoulos PI; Boumpas DT
    Ann Rheum Dis; 2006 Jun; 65(6):701-3. PubMed ID: 16699049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological disease modifying anti-rheumatic drugs.
    Cranwell-Bruce LA
    Medsurg Nurs; 2011; 20(3):147-50. PubMed ID: 21786492
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.
    Anderson P; Louie J; Lau A; Broder M
    Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
    Neovius M; Askling J
    Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
    Titos Arcos JC; Hallal H; Robles M; Andrade RJ
    Rev Esp Enferm Dig; 2012 May; 104(5):282-4. PubMed ID: 22662786
    [No Abstract]   [Full Text] [Related]  

  • 16. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biologic therapy with anti-TNFα in rheumathoid arthritis].
    Ferraccioli G
    Reumatismo; 2005; 57(4 Suppl):17-21. PubMed ID: 16385351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.
    Rose E; Lequerré T; Pouplin S; Daragon A; Le Loët X; Vittecoq O
    Joint Bone Spine; 2012 Jul; 79(4):421-2. PubMed ID: 22512937
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching between anti-TNFalpha agents: what is the evidence?
    Combe B
    Joint Bone Spine; 2004 May; 71(3):169-71. PubMed ID: 15182784
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.